- About Us
- Nano-Social Network
- Nano Consulting
- My Account
Alltracel Announces a NanopeuticsTM Product and Technology Development License Agreement with HemCon Medical Technologies to Serve the Military Market
Up front license fees and products expected to be on the market by 2008
Alltracel Pharmaceuticals Plc., ("Alltracel", or "the Company"), (AIM:AP.L), the Healthcare Innovation Group focused on the Woundcare, Oral Care, Dermal Health and Cardiovascular Health markets, today announces its NanopeuticsTM subsidiary has signed a licensing agreement for its technology with HemCon Medical Technologies, Inc., the haemorrhage control market leaders in military markets.
Following the successful completion of product concept testing in the US and the Czech Republic in Q2 NanopeuticsTM has agreed a technology development agreement focused on Chitosan- based NanospiderTM technology for advanced woundcare applications in all relevant markets.
An undisclosed license payment is payable immediately and will develop into a royalty revenue model for the completed Chitosan-NanospiderTM products which are expected to reach the market by 2008.
Commenting on the announcement, Tony Richardson, Alltracel's Chief Executive Officer said;
"The NanopeuticsTM technology has been well received in the market place, and today's announcement that HemCon Medical have decided to license our technology underpins the full potential it offers. HemCon is the leading haemorrhage control company serving the military markets and we are excited that we will be working together with their team to bring the NanospiderTM technology to market by 2008."
About Alltracel Pharmaceuticals Plc.
Alltracel, (AIM: AP.L) ( http://www.alltracel.com ) the Healthcare Innovation Group is focused on taking proprietary technology from research right through to commercialisation in the global healthcare market.
Alltracel Pharmaceuticals Plc., ("Alltracel") was founded in 1996 and is a public company which listed on London's Alternative Investment Market in July 2001.
With corporate headquarters in Dublin, Ireland; Alltracel has a commercial office in London, England; R&D subsidiary in the Czech Republic and manufacturing facilities in Shenzhen, China. Alltracel also has a wide network of research, development and manufacturing partners in Europe, Asia and North America.
Alltracel operates via two main divisions Alltracel Healthcare Group and Alltracel Healthcare Technologies:
Alltracel Healthcare Group is focused on the commercialisation effort behind proven innovative technologies and services for the global healthcare market. Alltracel Healthcare Group has a range of stake holdings, joint ventures and wholly owned business units operating in a variety of healthcare categories including Wound Care, Oral Care, and Cardiovascular Health.
- Alltracel's specialist Oral Care subsidiary Westone ( http://www.westoneproducts.com ) is headquartered in London, England and is the leading contract supply and manufacturing partner for the European private label inter-dental market. Westone also partners with a number of leading oral care brands internationally.
- Alltracel's specialist Nanotechnology subsidiary Nanopeutics s.r.o. ( http://www.nanopeutics.net ) is headquartered in Liberec in the Czech Republic and is dedicated to the commercialisation of NanospiderTM technology for the global healthcare market.
Alltracel Healthcare Technologies specialises in innovation, research, development and the deployment of proprietary technology in the global healthcare market. Alltracel Healthcare Technologies has established a substantial intellectual property portfolio with patents in a number of healthcare applications areas such as Wound Care, Cardiovascular Health and Skin Care.
m-docTM & PhytopeuticsTM are trademarks of Alltracel Pharmaceuticals plc.
NanospiderTM and NanopeuticsTM are trademarks controlled by Nanopeutics s.r.o.
This information is provided by RNS
The company news service from the London Stock Exchange
For more information, please click here
Dublin: Karen Muldowney
Alltracel: +353 1 235 2162
London: Deborah Scott
Financial Dynamics: +44 207 831 3113
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
New active filaments mimic biology to transport nano-cargo: A new design for a fully biocompatible motility engine transports colloidal particles faster than diffusion with active filaments January 11th, 2017
Strength of hair inspires new materials for body armor January 18th, 2017
Self-assembling particles brighten future of LED lighting January 18th, 2017